Glenmark's 'Digihaler' for asthma
PANAJI: Glenmark Pharmaceuticals Limited, launched 'Digihaler' “ India’s first digital dose inhaler (DDI) for asthma and chronic obstructive pulmonary disease (COPD) patients. This next-gen inhaler provides accurate digital dose counter along with low dose warning indicator.
Sujesh Vasudevan, president and head of India Formulations & Africa Region, Glenmark Pharmaceuticals, said, “India’s first digital dose inhaler (DDI) aims to enable patients to track the number of doses that have been consumed and prominently placed indicator provides a low dose warning which is beneficial to patients. This will further enable the doctors to determine patient’s adherence to the prescribed therapy regime.”
He said further, “Digihaler also addresses the issue of pseudo-adherence & tail-off phenomenon which leads to poor outcome of the therapy. With the launch of Digihaler, Glenmark is committed to provide innovative and world class products at affordable prices, and it further expands and strengthens our product offerings in the respiratory category too.”
